Total reported value
$1.7B
Reporting period: 2026-03-31 · Number of holdings: 36
Commodore Capital LP disclosed 36 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.7B and a quarterly turnover rate of 61.3%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "C"
Add ELVN
-30.2% $56.1M
Trim XENE
-54.2% -$32.7M
Trim SLNOEUR
-45.6% -$33.7M
Add ALKS
+18.3% $49.2M
Add ANRO
+49.4% $28.8M
Add NUVL
+51.6% $30.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RLAY | Relay Therapeutics INC | Stock-Other | 9.79% | +0.22% | — | |
| 2 | ALKS | Alkermes plc | Stock-Healthcare | 8.59% | +1.98% | +18.31% | |
| 3 | ELVN | Enliven Therapeutics INC | Stock-Other | 7.43% | +2.62% | -30.21% | |
| 4 | COGT | Cogent Biosciences INC | Stock-Other | 6.43% | +1.24% | +31.46% | |
| 5 | SYRE | Spyre Therapeutics INC | Stock-Other | 5.58% | +0.37% | -19.93% | |
| 6 | TYRA | Tyra Biosciences INC | Stock-Other | 5.48% | -0.43% | -26.67% | |
| 7 | CLDX | Celldex Therapeutics INC | Stock-Other | 4.95% | +0.31% | +5.13% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 4.94% | +1.26% | +51.56% | |
| 9 | AMLX | Amylyx Pharmaceuticals INC | Stock-Other | 4.54% | — | — | |
| 10 | KYMR | Kymera Therapeutics INC | Stock-Other | 3.61% | -0.27% | — | |
| 11 | ANRO | Alto Neuroscience INC | Stock-Other | 3.54% | +1.38% | +49.36% | |
| 12 | PHVS | Pharvaris N.V. | Stock-Other | 3.14% | -0.35% | +1.56% | |
| 13 | ERAS | Erasca INC | Stock-Other | 2.97% | +2.97% | NEW | |
| 14 | DMRA | Damora Therapeutics INC | Stock-Other | 2.91% | +2.91% | NEW | |
| 15 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 2.78% | -2.59% | -54.17% | |
| 16 | DFTX | Definium Therapeutics INC | Stock-Other | 2.19% | +2.19% | NEW | |
| 17 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 2.14% | -0.08% | — | |
| 18 | EYPT | Eyepoint INC | Stock-Other | 2.11% | +2.11% | NEW | |
| 19 | NRIX | Nurix Therapeutics INC | Stock-Other | 2.04% | -0.83% | — | |
| 20 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 1.91% | +1.91% | NEW | |
| 21 | ASMB | Assembly Biosciences INC | Stock-Other | 1.61% | -0.65% | — | |
| 22 | CATX | Perspective Therapeutics INC | Stock-Other | 1.53% | +1.53% | NEW | |
| 23 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 1.26% | -2.44% | -45.63% | |
| 24 | OCUL | Ocular Therapeutix INC | Stock-Other | 1.26% | +1.26% | NEW | |
| 25 | IPSC | Century Therapeutics INC | Stock-Other | 1.14% | +1.14% | NEW | |
| 26 | ✓ | Zura Bio LTD | Stock-Other | 1.12% | +1.12% | NEW | |
| 27 | SABS | Sab Biotherapeutics INC | Stock-Other | 0.98% | -0.12% | — | |
| 28 | PALI | Palisade Bio INC | Stock-Other | 0.73% | -1.06% | -37.26% | |
| 29 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 0.63% | +0.63% | NEW | |
| 30 | IKT | Inhibikase Therapeutics INC | Stock-Other | 0.52% | -0.22% | — | |
| 31 | ANTX | An2 Therapeutics INC | Stock-Other | 0.46% | +0.46% | NEW | |
| 32 | PEPG | Pepgen INC | Stock-Other | 0.46% | -1.01% | +31.62% | |
| 33 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.42% | -0.16% | — | |
| 34 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.29% | +0.29% | NEW | |
| 35 | LONA | Leonabio INC | Stock-Other | 0.28% | +0.05% | — | |
| 36 | RLMD | Relmada Therapeutics INC | Stock-Other | 0.26% | +0.26% | NEW |
Performance for Q3 2026
+21.9%
Performance Last 4 Quarters
+116.2%
Based on 83% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 36 | $1.7B | 61 | |
| 2025-12-31 | 33 | $1.5B | 72 | |
| 2025-09-30 | 37 | $2.0B | 71 | |
| 2025-06-30 | 33 | $1.4B | 0 | |
| 2025-03-31 | 31 | $1.4B | 100 | |
| 2024-12-31 | 31 | $1.4B | 0 | |
| 2024-09-30 | 36 | $1.6B | 0 | |
| 2024-06-30 | 35 | $1.5B | 0 | |
| 2024-03-31 | 39 | $1.5B | 0 | |
| 2023-12-31 | 32 | $1.1B | 0 | |
| 2023-09-30 | 30 | $855.5M | 0 | |
| 2023-06-30 | 26 | $889.8M | 0 | |
| 2023-03-31 | 32 | $656.8M | 0 | |
| 2022-12-31 | 35 | $663.5M | 0 | |
| 2022-09-30 | 30 | $621.9M | 0 | |
| 2022-06-30 | 24 | $473.0M | 0 | |
| 2022-03-31 | 27 | $447.7M | 0 | |
| 2021-12-31 | 25 | $431.8M | 0 | |
| 2021-09-30 | 29 | $379.3M | 0 | |
| 2021-06-30 | 29 | $287.0M | 0 | |
| 2021-03-31 | 31 | $251.0M | 0 | |
| 2020-12-31 | 28 | $183.9M | 0 |
Commodore Capital LP's most significant position changes for 2026-03-31: Sold out: Terns Pharmaceuticals INC (430); Sold out: Oruka Therapeutics INC (ORKA); New buy: Erasca INC (ERAS); New buy: Damora Therapeutics INC (DMRA); Sold out: Protagonist Therapeutics INC (PTGX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ELVN | Enliven Therapeutics INC | +2.6% | -30.21% | Trim |
| 2 | ALKS | Alkermes plc | +2% | +18.31% | Add |
| 3 | ANRO | Alto Neuroscience INC | +1.4% | +49.36% | Add |
| 4 | NUVL | Nuvalent Inc-a | +1.3% | +51.56% | Add |
| 5 | COGT | Cogent Biosciences INC | +1.2% | +31.46% | Add |
| 6 | SYRE | Spyre Therapeutics INC | +0.4% | -19.93% | Trim |
| 7 | CLDX | Celldex Therapeutics INC | +0.3% | +5.13% | Add |
| 8 | RLAY | Relay Therapeutics INC | +0.2% | — | Unchanged |
| 9 | LONA | Leonabio INC | +0.1% | — | Unchanged |
| 10 | AMLX | Amylyx Pharmaceuticals INC | — | — | Unchanged |
| 11 | LBRX | Lb Pharmaceuticals INC | -0.1% | — | Unchanged |
| 12 | SABS | Sab Biotherapeutics INC | -0.1% | — | Unchanged |
| 13 | AVTX | Avalo Therapeutics INC | -0.2% | — | Unchanged |
| 14 | IKT | Inhibikase Therapeutics INC | -0.2% | — | Unchanged |
| 15 | KYMR | Kymera Therapeutics INC | -0.3% | — | Unchanged |
| 16 | PHVS | Pharvaris N.V. | -0.4% | +1.56% | Add |
| 17 | TYRA | Tyra Biosciences INC | -0.4% | -26.67% | Trim |
| 18 | ASMB | Assembly Biosciences INC | -0.7% | — | Unchanged |
| 19 | NRIX | Nurix Therapeutics INC | -0.8% | — | Unchanged |
| 20 | PEPG | Pepgen INC | -1% | +31.62% | Add |
| 21 | PALI | Palisade Bio INC | -1.1% | -37.26% | Trim |
| 22 | SLNOEUR | Soleno Therapeutics INC | -2.4% | -45.63% | Trim |
| 23 | XENE | Xenon Pharmaceuticals INC | -2.6% | -54.17% | Trim |
| 24 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 25 | ORKA | Oruka Therapeutics INC | — | EXIT | Sold out |
| 26 | ERAS | Erasca INC | — | NEW | New buy |
| 27 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 28 | PTGX | Protagonist Therapeutics INC | — | EXIT | Sold out |
| 29 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 30 | EYPT | Eyepoint INC | — | NEW | New buy |
| 31 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| 32 | CTMX | Cytomx Therapeutics INC | — | EXIT | Sold out |
| 33 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 34 | CATX | Perspective Therapeutics INC | — | NEW | New buy |
| 35 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 36 | OCUL | Ocular Therapeutix INC | — | NEW | New buy |
| 37 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| 38 | ✓ | Zura Bio LTD | — | NEW | New buy |
| 39 | REPL | Replimune Group INC | — | EXIT | Sold out |
| 40 | KPTI | Karyopharm Therapeutics INC | — | NEW | New buy |
| 41 | CTNM | Contineum Therapeutics Inc-a | — | EXIT | Sold out |
| 42 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 43 | ANTX | An2 Therapeutics INC | — | NEW | New buy |
| 44 | ✓ | Helix Acquisition CORP Iii | — | NEW | New buy |
| 45 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 46 | DRUG | Bright Minds Biosciences INC | — | EXIT | Sold out |
Institutions with a similar AUM
CIK 0000928568
Total reported value
$1.7B
269 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001278430
Total reported value
$1.7B
8 stks
2018-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001773830
Total reported value
$1.7B
240 stks
2026-06-30
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0001335325
Total reported value
$362.2M
156 stks
2026-03-31
2 of the top 5 holdings overlap, including Cogent Biosciences INC
CIK 0001802528
Total reported value
$1.4B
12 stks
2026-03-31
2 of the top 5 holdings overlap, including Cogent Biosciences INC
CIK 0002011932
Total reported value
$193.3M
56 stks
2026-03-31
2 of the top 5 holdings overlap, including Cogent Biosciences INC